Related Experiment Videos
Interferon-alpha, unlike interferon-gamma, does not cause bone loss in the rat
G R Goodman1, I R Dissanayake, E Gorodetsky
1Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA.
Bone
|October 8, 1999
Summary
Interferon-alpha (IFN-alpha) did not harm bone metabolism in rats, despite clinical use. Low doses increased bone gla protein, but higher doses did not affect bone turnover or parathyroid hormone levels.
Area of Science:
- Biochemistry
- Endocrinology
- Pharmacology
Background:
- Interferons (IFN) are glycoproteins with diverse clinical applications.
- IFN-alpha is widely used for chronic hepatitis B and C.
- Limited research exists on IFN-alpha's in vivo effects on bone metabolism, with conflicting in vitro and in vivo data.
Purpose of the Study:
- To investigate the in vivo effects of IFN-alpha on bone metabolism in a rat model.
- To address the importance of understanding IFN-alpha's impact on bone due to its extensive clinical use.
Main Methods:
- Rats received low, intermediate, or high doses of IFN-alpha for 28 days.
- Serum osteocalcin (bone gla protein, BGP) and parathyroid hormone (PTH) were measured.
- Histomorphometric analysis of bone was performed after double labeling.
Main Results:
- IFN-alpha did not alter histomorphometric parameters or affect PTH levels.
- Low-dose IFN-alpha significantly increased serum BGP on days 14 and 28.
- Intermediate and high doses of IFN-alpha did not significantly affect serum BGP.
Conclusions:
- The study found no evidence of deleterious effects of IFN-alpha on bone metabolism in rats.
- Results align with limited clinical studies, suggesting IFN-alpha's safety for bone health at tested doses.